possible involvement of different corepressors in the actions of different antiestrogens and unliganded ER, we have constructed a focused phage display library which contains the "CoRNR box" motif, a binding site important for N-CoR/SMRT to interact with the nuclear receptors. In this report, we have shown that screening of the CoRNR box library with ER treated with no hormone or different antiestrogens led to the isolation of peptides that differentially interact with apo-ER, tamoxifen-bound ER, or ICI 182,780-bound ER.
These interactions observed in vitro have also been confirmed in vivo using a mammalian two-hybrid assay. Using a series of ER mutants, we were able to show that these CoRNR box-containing peptides have different binding characteristics from the peptides that contain the coactivator LXXLL motif These peptides can be used to probe the conformational changes of ER induced by different antiestrogens and will be valuable for the design of screens for novel ER-antagonists. 14 
Introduction
The antiestrogen tamoxifen is the most commonly used endocrine treatment for all stages of breast cancer. Tamoxifen is a SERM (Selective Estrogen Receptor Modulator) which can act as an estrogen or an antiestrogen depending on the tissues in which it operates. Initially, tamoxifen may have profound effects on the survival and proliferation of breast cancer cells, but progressively, resistance emerges through mechanisms that are only partially understood. Some pure antiestrogens lack cross-resistance with tamoxifen, thus makes them good candidates as second-line therapy for patients who develop tamoxifen resistance and also suggests that the mechanisms underlying the actions of SERMs and pure antagonists are very different. This proposal investigates the possible involvement of different corepressor proteins in mediating the actions of different classes of antiestrogens. To probe the changes in the structure of the estrogen receptor (ER) upon binding of different antiestrogens, a focused phage displayed peptide library which expresses peptides containing a "CoRNR box" motif, important for corepressor to bind nuclear receptor, was made. Peptides that differentially interact with ER occupied by different antiestrogens were obtained. These peptides had provided a better understanding of actions of different antiestrogens and the assay which detects the peptide-ER interaction can be used as a sensitive and efficient system to screen for novel antiestrogens.
Body
In the previous two granting periods, we identified CoRNR box pepitdes which interact with ER only in the absence of hormone or in the presence of antiestrogens. Interaction of these CoRNR peptides with ER was also confirmed in cells using mammalian two-hybrid assay. A series of ER mutants were generated to define the regions within ER required for CoRNR box peptide binding. For comparison, LXXLL motif-containing peptides were also included. The LXXLL is a motif found in all p160 coactivators and required for these coactivators to interact with the estrogen receptor. The LXXLL peptides used in this study have been previously shown to interact with ER only in the presence of agonist but not in the presence of SERMs or pure antagonists (1) . Mutations at the amino acid residues Lys-362 and Val-376 within ERca decreased its ability to interact with both the CoRNR and LXXLL peptides, suggesting that the binding surfaces for these two classes of peptides are close or overlapping. Mutation at Leu-372, however, totally abolished the interaction between ERCC and two of the CoRNR peptides (bT1 and b12) while having no effect on binding of the LXXLL peptides to the receptor. Thus, although the binding sites on ERa for the CoRNR and LXXLL peptides are closely linked, they can be functionally separated.
The major task in this last granting period is to further dissect the mechanism of ER action using CoRNR peptides and ER-L372R. * Examination of the possible involvement of corepressors other than NCoR/SMRT in regulating the transcriptional activity of ER There is strong evidence that corepressors NCoR and SMRT canmodulate the agonist activity of tamoxifen, but they play little, if any, role in regulating the physiological actions of estradiol (2, 3) . In the 2004 annual summary, we had reported that one ERcc mutant, ER-L372R, lost the ability to interact with two of the CoRNR box-containing peptides. Binding of ER-L372R to LXXLL motif-containing peptides, however, was not affected. Predictably, we observed that the agonist activity of tamoxifen was enhanced by disruption of the putative corepressor binding surface (defined by the L372R mutation) on ERa. However, one of the most interesting findings of our study was that this mutation also enhanced the agonist efficacy of estradiol. One possible explanation is that this mutation disrupts the interactionof ER with a corepressor (or a competitive repressor) that, unlike NCoR and SMRT, can recognize the agonist-activated structure of ERa. One potential candidate that could function in this manner is REA (repressor of estrogen receptor activity).
REA potentiates the inhibitory activity of antiestrogen-liganded ER and represses the transcriptional activity of the estradiol-liganded ER (4). Neutralization of endogenous REA using antisense REA enhances ER transcriptional activity mediated by estradiol (5) . It has been shown that REA can interact with ER in the presence of estradiol or tamoxifen, which dampens the stimulatory response of ER to these two ligands. REA-interacting domain of the ER has been localized between amino acids 304-530. The observation of the enhanced transcriptional activity of ER-L372R led us to hypothesize that REA may interact with ER through Leu-372. To test this hypothesis, HepG2 cells were transfected with an expression vector for the wild-type ER (ER-WT) or ER-L372R and the reporter construct 3xERE-TATA-Luc in the absence or presence of increasing amounts of an expression vector for REA and cells were then treated with estradiol. As shown in Figure IA , REA can repress 30% of the estradiol-mediated wild-type ER transcriptional activity. If Leu-372 is important for interacting with REA, mutation at this amino acid should disrupt the REA-ER interaction and REA can no longer inhibit ER activity. However, Figure lB showed that REA can also suppress 30% of the ER-L372 activity induced by estradiol. It is possible that other corepressors may be involved in mediating ER activity through Leu-372.
0 Increased interaction with known LXXLL motif-containing peptides may partly account for the enhanced transcriptional activity of the ER-L372R mutant Another possible explanation for the enhanced transcriptional activity of ER-L372R is that mutation of Leu-372 to an arginine may inadvertently increase the affinity of the receptor for coactivators by making additional contacts with the amino acid residues adjacent to the LXXLL motif. To test this hypothesis, the abilities of wild-type ERcX and ER-L372R to interact with different classes of LXXLL-containingpeptides were compared in the presence of increasing concentrations of estradiol using a mammalian two-hybrid assay (Figure 2 ). Three LXXLL peptides D 11, D47, and F6 with distinct receptor binding characteristics (1) were used. The GRIPI NR-box peptide contains the middle three copies of the LXXLL motif found in the coactivator GRIP I. The SRC-1 NR-boxpeptide contains the middle three copies of the LXXLL motif found in the coactivator SRC-1. As shown in Figure 2 , compared with the wild-type ERx, the ER-L372R mutant did not show a higher affinity for any of the LXXLL peptides tested. However, ER-L372R did exhibit a higher capacity for binding to the GRIPI NR-box peptide at higher concentrations of estradiol. Therefore, the enhanced transcriptional activity of ER-L372R can be explained in part by increased coactivator binding. Given the overlapping nature of the corepressor and coactivator binding site on ERca, it is likely that the increased transcriptional activity of ER-L372R is due to both a loss ofcorepressor binding and an increase in the ability of coactivators to bind to the receptor.
* The ER-L372R mutant is not hypersensitive to estradiol
The dramatically enhanced estradiol-dependent transcriptional activity of ER-L372R prompted us to examine whether this mutant receptor displayed an increased sensitivity to estradiol. To address this issue, HepG2 cells were transfected with 10 ngof either the wild-type ERcL or ER-L372R expression vector along with 3 xERE-TATA-Luc reporter and subsequently treated with increasing concentrations of estradiol (Figure 3) . Contrary to what was expected, we observed that the mutant receptor was about one order of magnitude less sensitive to estradiol than the wild-type receptor. These results suggest that mutation at Leu-372 of ERCC did not render the receptor more sensitive to estradiol treatment.
* ER-interacting CoRNR peptides show distinct preferences for other nuclear receptors
It has been shown that different members of the nuclear receptor superfamily display distinct preferences for the known IDs (receptor-interacting domains) located within NCoR and SMRT (6) . Consequently, we examined the binding specificity of the ER-interacting CoRNR peptides with other nuclear receptors using the mammalian two-hybrid assay. Surprisingly, although these peptides were designed using the CoRNR box consensus derived from NCoR and SMRT, which interacts with both apo-RARa and apo-TRB, none of the CoRNR box-containing peptides obtained in this study interacted with these two receptors. However, we noticed that the bN2 peptide can interact with apo-RXRac, and treatment with 9-cis-retinoic acid abolished this interaction (Figure 4 ). Under the same conditions apo-RXR showed only minimal binding to NCoR/SMRT IDs, and the interaction between SMRT ID-C and apo-RXR was actually slightly increased, rather than inhibited, by retinoic acid treatment, consistent with previous observations that RXRa only weakly interacts with SMRT, and retinoic acid treatment can strengthen this interaction (6, 7). The binding of progesterone receptor (PR) to ER-interacting CoRNR peptides was also examined. Figure 4 showed that no interaction of PRAand PRB with the CoRNR peptides was observed in the absence of hormone or in the presence of progesterone. However, treatment with RU486 (a mixed agonist/antagonist) or ZK98299 (a pure antagonist) facilitated a robust interaction between both PR isoforms and the bT1 peptide. As antagonist-bound PRs can interact with NCoR/SMRT IDs, as shown in Figure 4 , and in previous studies (8), it is not surprising that CoRNR box-containing peptides with this binding specificity were found in our screens. However, there are differences in the CoRNR box binding patterns of PR treated with RU486 or ZK98299. The bT1 peptide, which binds tamoxifen-bound ERca and ERB, associates more stronglywith PRs treated with RU486 than ZK98299, whereas NCoR/SMRT ID-Cs exhibit a stronger interaction with ZK98299-bound PRs than RU486-bound PRs. These results demonstrated that the flanking sequences of the CoRNR box can dictate the receptor binding specificity and that an unidentified corepressor(s) other thanNCoR/SMRT might exist that shares the CoRNR box motif, but differentially interacts with different nuclear receptors. 
Key Research Accomplishments

Conclusion
The main goal of this proposal is to use combinatorial phage display to screen for corepressor-like peptides (CoRNR box-containing peptides) that bind selectively to apo-ER, tamoxifen-bound ER, and ICI 182,780-bound ER and to use these peptides to further understand the molecular mechanism of ER action. We have successfully completed Task 1 and identified three different classes of CoRNR peptides whose ability to interact with ER was influenced by the nature of the bound ligand. As shown in the previous two annual reports and in this final report, these CoRNR peptides have helped map a negative regulatory surface within ERa. Our findings are consistent with the existence of corepressors that interact with and modulate ERca activity. These studies have provided a better understanding of ER action and the assays developed from this research will be valuable for the design of screens for novel ER-antagonists for the treatment of breast cancer.
A. Figure 1 . REA suppresses the transcriptional activity of wild-type ER and ER-L372R. HepG2 cells were transfected with 1 Ong of (A) wild-type or (B) mutant ERco along with 3xERE-TATA-Luc reporter, the 13-galactosidase control plasmid, and an increasing concentrations of REA. Following transfection, cells were treated with estradiol (100 nM) for 24 h before harvested for luciferase and P3-galactosidase activity. Luciferase activity is presented relative to the response estradiol in the presence of the ER alone, which is set at 100%. Numbers at the top of the leftmost bar show the fold induction in luciferase activity by estradiol in the absence of added REA.
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Figure 4. ER-Interacting CoRNR Peptides Show Distinct Preferences for Other Nuclear
Receptors. The ability of the CoRNR box-containing peptides to interact with RXRa (A), PRB (B), or PRA (C) was tested using mammalian two-hybrid assays. HepG2 cells were transfected with VP 16-receptor fusion expression vector along with the Gal4-DBD-peptide fusion construct, the 5xGal4-TATA-Luc reporter, and the B-galactosidase control plasmid. After transfection, cells were treated with 100 nM hormone for 24 h before being harvested for determination of luciferase activity. Data are presented as normalized luciferase activity, which was obtained by dividing luciferase activity by B-galactosidase activity.
